Literature DB >> 16091480

Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal.

Wichert J Kuijt1, Stephen A Huang.   

Abstract

CONTEXT: The preparation for radioiodine administration recommended by the current pediatric literature is a 6-wk withdrawal that typically includes the transient administration of T3. Compared with adults, T4 clearance rates and serum TSH to free T4 ratios are higher in children, implying that pediatric patients can achieve adequate hyperthyrotropinemia with shorter levothyroxine withdrawals.
OBJECTIVE: The objective of this study was to determine whether children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia using an abbreviated levothyroxine withdrawal protocol.
DESIGN: The study design was a retrospective analysis of 15 consecutive levothyroxine withdrawals performed without T3 at Children's Hospital Boston. PATIENTS: Eleven children with differentiated thyroid cancer were included. The average age at the time of withdrawal was 12.5 +/- 0.8 yr. MAIN OUTCOME MEASUREMENT: Serum TSH concentrations obtained after the discontinuation of levothyroxine were analyzed to determine the time interval required to achieve a serum TSH level greater than 25 microU/ml for each patient.
RESULTS: Adequate hyperthyrotropinemia was documented in all children tested by d 14. The mean interval required to achieve a serum TSH level above 25 microU/ml from a suppressed serum TSH was 12.3 +/- 0.7 d.
CONCLUSIONS: Shorter withdrawals minimize hypothyroid morbidity and the theoretical risk of decreased 131micro)I residence time from excessive hyperthyrotropinemia. These benefits are amplified in children due to their high incidence of distant metastases. We propose an abbreviated 2-wk withdrawal protocol to facilitate the adjunctive therapy and surveillance of children with follicular cell-derived cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091480     DOI: 10.1210/jc.2005-1085

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

2.  Age and the thyrotropin response to hypothyroxinemia.

Authors:  Rebecca Over; Sonia Mannan; Hala Nsouli-Maktabi; Kenneth D Burman; Jacqueline Jonklaas
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

3.  In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.

Authors:  Laticia A Valle; Revital L Gorodeski Baskin; Kyle Porter; Jennifer A Sipos; Raheela Khawaja; Matthew D Ringel; Richard T Kloos
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

4.  TSH regulation dynamics in central and extreme primary hypothyroidism.

Authors:  Marisa C Eisenberg; Ferruccio Santini; Alessandro Marsili; Aldo Pinchera; Joseph J DiStefano
Journal:  Thyroid       Date:  2010-11       Impact factor: 6.568

5.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

6.  Simulation of post-thyroidectomy treatment alternatives for triiodothyronine or thyroxine replacement in pediatric thyroid cancer patients.

Authors:  Rotem Ben-Shachar; Marisa Eisenberg; Stephen A Huang; Joseph J DiStefano
Journal:  Thyroid       Date:  2012-05-11       Impact factor: 6.568

7.  Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.

Authors:  Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze
Journal:  Endocr Relat Cancer       Date:  2022-09-07       Impact factor: 5.900

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.